The consortium of IT-DED³ is composed of 7 beneficiaries and 9 partners from 8 different European countries. In total, the project has 7 participating organisations from the non-academic sector.  

The IT-DED³ consortium has a holistic bench-to-bedside approach and intends to go from R&D to proof of concept with a patient- and disease-driven mind set. To achieve the objectives of the project, we have gathered internationally recognized experts in the following relevant disciplines: medicinal and organic chemistry, validated and new in vitro and in vivo models for dry eye disease, formulation for ocular drug delivery, ophthalmologists, ocular surface experts and clinicians combined with state of the art research facilities.